Kenneth C Anderson Selected Research

elotuzumab

12/2021	Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma.
1/2018	Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
1/2018	Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.
11/2017	Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma.
12/2015	Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.
8/2015	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
6/2012	Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.
8/2008	Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kenneth C Anderson Research Topics

Disease

512	Multiple Myeloma 06/2022 - 01/2002
256	Neoplasms (Cancer) 01/2022 - 01/2002
33	Waldenstrom Macroglobulinemia (Macroglobulinemia) 11/2021 - 04/2003
30	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 04/2002
18	Disease Progression 01/2022 - 06/2005
16	Lymphoma (Lymphomas) 01/2022 - 04/2003
15	Thrombocytopenia (Thrombopenia) 01/2022 - 05/2002
11	Neutropenia 01/2022 - 12/2004
10	Plasmacytoma 01/2017 - 09/2002
10	Peripheral Nervous System Diseases (PNS Diseases) 12/2015 - 07/2006
9	Residual Neoplasm 10/2021 - 01/2011
9	Anemia 11/2018 - 01/2009
8	Fatigue 01/2022 - 07/2006
8	Leukemia 10/2019 - 04/2002
8	Bone Diseases (Bone Disease) 01/2019 - 01/2002
7	Carcinogenesis 01/2019 - 10/2007
6	Chromosomal Instability (Chromosome Stability) 09/2015 - 07/2002
5	Breast Neoplasms (Breast Cancer) 08/2021 - 02/2011
5	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 11/2011 - 07/2005
4	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 11/2021 - 07/2006
4	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2019 - 02/2005
4	Paraproteinemias (Monoclonal Gammopathy) 03/2016 - 09/2008

Drug/Important Bio-Agent (IBA)

147	Bortezomib (Velcade)FDA Link 01/2022 - 05/2002
75	Proteasome InhibitorsIBA 04/2022 - 05/2002
68	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 02/2002
66	Lenalidomide (CC 5013)FDA Link 01/2022 - 11/2002
48	Pharmaceutical PreparationsIBA 10/2021 - 01/2002
40	Thalidomide (Thalomid)FDA Link 01/2021 - 04/2002
39	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2002
36	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2022 - 10/2002
30	Biological ProductsIBA 10/2021 - 01/2002
28	Interleukin-6 (Interleukin 6)IBA 10/2021 - 05/2002
27	Immunomodulating AgentsIBA 11/2021 - 05/2002
25	Monoclonal AntibodiesIBA 12/2021 - 04/2003
24	CytokinesIBA 09/2011 - 05/2002
23	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2016 - 02/2002
22	AntigensIBA 12/2021 - 04/2003
22	Melphalan (Alkeran)FDA LinkGeneric 01/2018 - 07/2002
18	NF-kappa B (NF-kB)IBA 07/2013 - 05/2002
17	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 12/2021 - 05/2005
15	pomalidomideIBA 01/2022 - 09/2006
14	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 03/2003
12	Histone Deacetylase InhibitorsIBA 01/2018 - 04/2003
11	Biomarkers (Surrogate Marker)IBA 10/2021 - 10/2007
11	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 03/2002
11	Peptides (Polypeptides)IBA 01/2021 - 06/2003
10	Immunoconjugates (Immunoconjugate)IBA 12/2021 - 07/2004
10	MicroRNAs (MicroRNA)IBA 01/2020 - 04/2009
10	EnzymesIBA 01/2018 - 10/2003
10	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 11/2014 - 01/2003
9	Immunoglobulins (Immunoglobulin)IBA 02/2022 - 03/2002
9	UbiquitinIBA 01/2022 - 08/2006
9	B-Cell Maturation AntigenIBA 12/2021 - 07/2006
9	Histone Deacetylases (Histone Deacetylase)IBA 01/2020 - 10/2003
9	Phosphotransferases (Kinase)IBA 12/2017 - 03/2004
9	perifosineIBA 08/2012 - 05/2006
8	elotuzumabIBA 12/2021 - 08/2008
8	LigandsIBA 10/2021 - 03/2002
8	Vorinostat FDA Link 01/2016 - 04/2003
8	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2015 - 10/2002
8	tanespimycin (17AAG)IBA 12/2011 - 02/2006
8	Insulin-Like Growth Factor I (IGF-1)IBA 01/2009 - 08/2002
8	Telomerase (Telomerase Reverse Transcriptase)IBA 08/2008 - 04/2002
7	daratumumabIBA 12/2021 - 02/2011
7	Immunoglobulin M (IgM)IBA 11/2021 - 04/2003
7	Alkylating AgentsIBA 01/2021 - 08/2006
7	carfilzomibIBA 10/2020 - 07/2013
7	Prednisone (Sone)FDA LinkGeneric 01/2018 - 08/2005
7	Immunoglobulin G (IgG)IBA 07/2014 - 07/2005
7	Rituximab (Mabthera)FDA Link 09/2010 - 01/2005
7	Antineoplastic Agents (Antineoplastics)IBA 05/2010 - 09/2002
6	Histones (Histone)IBA 10/2021 - 05/2009
6	Messenger RNA (mRNA)IBA 01/2021 - 04/2002
6	AntibodiesIBA 11/2019 - 03/2002
6	marizomibIBA 09/2016 - 11/2005
6	PanobinostatIBA 10/2013 - 11/2011
6	CaspasesIBA 06/2013 - 11/2003
6	GlucocorticoidsIBA 07/2012 - 01/2005
6	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 07/2009 - 04/2003
6	Cytotoxins (Cytolysins)IBA 04/2009 - 07/2004
6	Insulin-Like PeptidesIBA 01/2009 - 07/2002
6	InterleukinsIBA 01/2009 - 05/2004
5	isatuximabIBA 01/2022 - 08/2017
5	Complement System Proteins (Complement)IBA 01/2020 - 04/2003
5	ixazomibIBA 01/2018 - 08/2011
5	Zoledronic Acid (Zometa)FDA Link 03/2016 - 02/2009
5	Sirolimus (Rapamycin)FDA Link 11/2014 - 12/2004
5	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 12/2012 - 06/2005
5	enzastaurinIBA 07/2011 - 02/2007
5	Protein Kinase CIBA 02/2009 - 05/2004
4	Chimeric Antigen ReceptorsIBA 12/2021 - 11/2019
4	Transforming Growth Factor beta (TGF-beta)IBA 01/2020 - 01/2007
4	Transcription Factors (Transcription Factor)IBA 01/2019 - 06/2002
4	Caspase 3 (Caspase-3)IBA 08/2017 - 09/2005

Therapy/Procedure

201	Therapeutics 06/2022 - 01/2002
27	Drug Therapy (Chemotherapy) 01/2021 - 01/2002
22	Immunotherapy 01/2022 - 06/2003
21	Stem Cell Transplantation 01/2022 - 01/2002
11	Transplantation 01/2022 - 01/2002
4	Precision Medicine 12/2021 - 10/2015